Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GE molecular diagnostics

This article was originally published in The Gray Sheet

Executive Summary

General Electric reaffirms its interest in supplementing imaging with in vitro diagnostics Oct. 1 with a three-year agreement with Eli Lilly to develop molecular assays that help target cancer therapies. The multiplexed tissue tests being developed at GE Healthcare and GE Global Research aim to identify protein and gene signatures to predict whether Eli Lilly's drugs will be effective. The collaboration follows the collapse of GE's planned buyout of part of Abbott's diagnostics business for $8 billion in July (1"The Gray Sheet" July 16, 2007, p. 3)
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

MT025335

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel